Bristol-Myers Squibb Co. (BMY) Cash Flow Statement

Click line-items for a historical chart and %

Cash Flows From Operating Activities:
Net Earnings	2.5B
Adjustments to reconcile net earnings to net cash provided by operating activities:
Net earnings attributable to noncontrolling interest	-541M
Depreciation
Amortization
Impairment charges
Deferred income tax expense	-1.23B
Stock-based compensation expense	154M
Other adjustments	-35M
Changes in operating assets and liabilities:
Receivables	648M
Inventories	-103M
Accounts payable	-232M
Deferred income	3.57B
U.S. and foreign income taxes payable	-50M
Other	-897M
Net Cash Provided by Operating Activities	6.94B
Cash Flows From Investing Activities:
Proceeds from sale and maturities of marketable securities	4.89B
Purchases of marketable securities	-3.61B
Additions to property, plant and equipment and capitalized software	-548M
Proceeds from sale of businesses and other investing activities
Proceeds from sale of businesses and other investing activities	68M
Net Cash Used in Investing Activities	-6.73B
Cash Flows From Financing Activities:
Short-term debt borrowings/(repayments)	49M
Long-term debt borrowings	1.95B
Long-term debt repayments	-2.11B
Interest rate swap terminations	2M
Issuances of common stock	463M
Common stock repurchases	-2.4B
Dividends paid	-2.29B
Net Cash Used in Financing Activities	-4.33B
Effect of Exchange Rates on Cash and Cash Equivalents	-1M
(Decrease)/Increase in Cash and Cash Equivalents	-4.12B
Cash and Cash Equivalents at Beginning of Period	5.78B
Cash and Cash Equivalents at End of Period	1.66B

Entities mentioned with BMY

View All Entities